Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 41

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
	(63,645,218
			)

			(58,589,013
			)

			Total shareholders' equity

			14,132,126

			1,981,155

			Total liabilities and shareholders' equity

			$
			14,804,800

			$
			3,813,982

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

3

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Operations

			Three Months Ended

			Nine Months Ended 

			June 30, 2025

			June 30, 2024

			June 30, 2025

			June 30, 2024

			Expenses:

			Research and development

			$
			939,067

			$
			897,305

			$
			2,443,191

			$
			2,778,100

			General and administrative

			964,676

			1,035,140

			2,998,127

			3,232,248

			Loss from operations

			(1,903,743
			)

			(1,932,445
			)

			(5,441,318
			)

			(6,010,348
			)

			Other income :

			Reimbursement grant income

			183,281

			236,226

			536,744

			661,062

			Interest income

			572

			32,848

			2,503

			137,007

			Misc other income

			-

			-

			-

			14,766

			Foreign exchange loss

			(29,574
			)

			(4,841
			)

			(54,294
			)

			(9,681
			)

			154,279

			264,233

			484,953

			803,154

			Loss before income taxes

			(1,749,464
			)

			(1,668,212
			)

			(4,956,365
			)

			(5,207,194